NCT00301262

Brief Summary

Men's quality of life (QoL) is potentially affected by mild erectile dysfunction (ED) to the same extent as it is by moderate and severe ED. This study will provide controlled clinical data measuring efficacy, QoL parameters and satisfaction changes in men with mild ED treated with Viagra versus those treated with a placebo. With an open-label extension, this study will also provide all study subjects the opportunity to receive the active drug treatment for 6 weeks.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
183

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Nov 2005

Geographic Reach
1 country

26 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2005

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

March 7, 2006

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 10, 2006

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2007

Completed
1.3 years until next milestone

Results Posted

Study results publicly available

December 9, 2008

Completed
Last Updated

February 1, 2021

Status Verified

January 1, 2021

Enrollment Period

1.8 years

First QC Date

March 7, 2006

Results QC Date

November 12, 2008

Last Update Submit

January 28, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Index at the End of the DB Treatment (Week 8)

    adjusted mean : Possible scores for the EDITS Index range from 0 (extremely low treatment satisfaction) to 100 (extremely high treatment satisfaction).

    Week 8

Secondary Outcomes (48)

  • Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Index

    Week 8, Week 14

  • Change From Baseline to End of Double-Blind Phase (Week 8) in Patient Reported Erectile Function Assessment (PREFA) Total Score

    Week 8

  • Patient Reported Erectile Function Assessment (PREFA) Total Score

    Week 8, Week 14

  • Change From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Erectile Function

    Week 8

  • Change From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Orgasmic Function

    Week 8

  • +43 more secondary outcomes

Interventions

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men above age of majority
  • Mild erectile dysfunction (IIEF-EF 22-25) and sexual dissatisfaction (IIEF-OS 7 or less)

You may not qualify if:

  • Use of more than 4 doses of any PDE5 inhibitor in the past 12 weeks and use of any PDE5 inhibitor in the past 4 weeks
  • Subjects currently taking any other commercially available drug or non-drug treatment for ED

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (26)

Pfizer Investigational Site

Calgary, Alberta, T2L 1K8, Canada

Location

Pfizer Investigational Site

Calgary, Alberta, T2V 4R6, Canada

Location

Pfizer Investigational Site

Edmonton, Alberta, T5H 4B9, Canada

Location

Pfizer Investigational Site

Langley, British Columbia, V3A 4H9, Canada

Location

Pfizer Investigational Site

Surrey, British Columbia, V3V 1N1, Canada

Location

Pfizer Investigational Site

Vancouver, British Columbia, V5Z 1K3, Canada

Location

Pfizer Investigational Site

Vancouver, British Columbia, V6Z 2T1, Canada

Location

Pfizer Investigational Site

Victoria, British Columbia, V8T 5G1, Canada

Location

Pfizer Investigational Site

Bay Roberts, Newfoundland and Labrador, A0A 1G0, Canada

Location

Pfizer Investigational Site

Halifax, Nova Scotia, B3H 3A7, Canada

Location

Pfizer Investigational Site

Barrie, Ontario, L4M 7G1, Canada

Location

Pfizer Investigational Site

Corunna, Ontario, N0N 1G0, Canada

Location

Pfizer Investigational Site

Kingston, Ontario, K7L 3J7, Canada

Location

Pfizer Investigational Site

London, Ontario, N6A 4V2, Canada

Location

Pfizer Investigational Site

Oakville, Ontario, L6H 3P1, Canada

Location

Pfizer Investigational Site

Sarnia, Ontario, N7T 4X3, Canada

Location

Pfizer Investigational Site

Toronto, Ontario, M5T 2S8, Canada

Location

Pfizer Investigational Site

Toronto, Ontario, M6A 3B5, Canada

Location

Pfizer Investigational Site

Chicoutimi, Quebec, G7H 4A3, Canada

Location

Pfizer Investigational Site

L'Ancienne-Lorette, Quebec, G2E 2X1, Canada

Location

Pfizer Investigational Site

Montreal, Quebec, H2L 5B1, Canada

Location

Pfizer Investigational Site

Montreal, Quebec, H2X 1N8, Canada

Location

Pfizer Investigational Site

Montreal, Quebec, H3S 1Z1, Canada

Location

Pfizer Investigational Site

Pointe-Claire, Quebec, H9R 4S3, Canada

Location

Pfizer Investigational Site

Saint-Léonard, Quebec, H1S 3A9, Canada

Location

Pfizer Investigational Site

Sherbrooke, Quebec, J1H 1Z1, Canada

Location

Related Publications (1)

  • Kaminetsky JC, Stecher V, Tseng LJ. Quality of erections by age group in men with erectile dysfunction. Int J Clin Pract. 2017 Oct;71(10). doi: 10.1111/ijcp.12976. Epub 2017 Sep 11.

Related Links

MeSH Terms

Conditions

Erectile Dysfunction

Interventions

Sildenafil Citrate

Condition Hierarchy (Ancestors)

Genital Diseases, MaleGenital DiseasesUrogenital DiseasesSexual Dysfunction, PhysiologicalMale Urogenital DiseasesSexual Dysfunctions, PsychologicalMental Disorders

Intervention Hierarchy (Ancestors)

SulfonamidesAmidesOrganic ChemicalsSulfonesSulfur CompoundsPiperazinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Results Point of Contact

Title
Pfizer ClinicalTrials.gov Call Center
Organization
Pfizer, Inc.

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 7, 2006

First Posted

March 10, 2006

Study Start

November 1, 2005

Primary Completion

September 1, 2007

Study Completion

September 1, 2007

Last Updated

February 1, 2021

Results First Posted

December 9, 2008

Record last verified: 2021-01

Locations